Pharmacokinetics and toxicity of bromide following high-dose oral potassium bromide administration in healthy Beagles

• Published in: Journal of veterinary pharmacology and therapeutics Vol. 25; no. 6; pp. 425 - 432
• Main Authors: March, P. A., Podell, M., Sams, R. A.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Science Ltd 01.12.2002
• Subjects: Administration, Oral; Animals; Bromides - metabolism; Bromides - pharmacokinetics; Bromides - toxicity; Dogs; Evoked Potentials, Auditory - drug effects; Female; Half-Life; Male; Metabolic Clearance Rate; Potassium Compounds - metabolism; Potassium Compounds - pharmacokinetics; Potassium Compounds - toxicity
• ISSN: 0140-7783; 1365-2885
• DOI: 10.1046/j.1365-2885.2002.00440.x

The pharmacokinetics of a multidose regimen of potassium bromide (KBr) administration in normal dogs was examined. KBr was administered at 30 mg/kg p.o. q 12 h for a period of 115 days. Serum, urine, and cerebrospinal fluid (CSF) bromide (BR) concentrations were measured at the onset of dosing, during the accumulation phase, at steady‐state, and after a subsequent dose adjustment. Median elimination half‐life and steady‐state serum concentration were 15.2 days and 245 mg/dL, respectively. Apparent total body clearance was 16.4 mL/day/kg and volume of distribution was 0.40 L/kg. The CSF:serum BR ratio at steady‐state was 0.77. Dogs showed no neurologic deficits during maintenance dosing but significant latency shifts in waves I and V of the brainstem auditory evoked response were evident. Following a subsequent dose adjustment, serum BR concentrations of approximately 400 mg/dL were associated with caudal paresis in two dogs. Estimated half‐life during the accumulation phase was shorter than elimination half‐lives reported in other studies and was likely related to dietary chloride content. The range of steady‐state concentrations achieved suggests individual differences in clearance and bioavailability between dogs. The described protocol reliably produced serum BR concentrations that are required by many epileptic patients for satisfactory seizure control.